

**Appendix Table F63. Clinical outcomes after fesoterodine vs. placebo**

Reference	Mg/day	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable/1000 events (95% CI)
<b>Any adverse events</b>						
Cardozo, 2010 <sup>476*</sup>	4	867	1.21 (1.07; 1.38)	0.100 (0.033; 0.166)	10 (6; 30)	100 (33; 166)
	8	882	1.39 (1.23; 1.57)	0.181 (0.117; 0.246)	6 (4; 9)	181 (117; 246)
<b>Discontinuations</b>						
Dmochowski, 2010 <sup>474</sup>	4 to 8	883	0.95 (0.68; 1.33)	-0.007 (-0.052; 0.038)		
Herschorn, 2010 <sup>475</sup>	4 to 8	1013	1.33 (0.89; 1.98)	0.029 (-0.010; 0.069)		
<b>Adverse events leading to discontinuation</b>						
Dmochowski, 2010 <sup>474</sup>	4 to 8	883	1.64 (0.97; 2.79)	0.030 (-0.001; 0.062)		
Herschorn, 2010 <sup>475</sup>	4 to 8	1013	3.61 (1.55; 8.38)	0.047 (0.023; 0.070)	21 (14; 43)	47 (23; 70)
<b>Lack of efficacy leading to discontinuation</b>						
Dmochowski, 2010 <sup>474</sup>	4 to 8	883	0.32 (0.12; 0.86)	-0.025 (-0.044; -0.005)	-41 (-218; -22)	-25 (-44; -5)
Herschorn, 2010 <sup>475</sup>	4 to 8	1013	1.28 (0.46; 3.56)	0.004 (-0.012; 0.021)		
<b>Deterioration on the PPBC scale</b>						
Dmochowski, 2010 <sup>474</sup>	4 to 8	883	0.49 (0.26; 0.92)	-0.033 (-0.061; -0.005)	-30 (-201; -16)	-33 (-61; -5)
<b>Deterioration on the UPS scale</b>						
Dmochowski, 2010 <sup>474</sup>	4 to 8	883	0.85 (0.51; 1.42)	-0.010 (-0.042; 0.022)		
<b>Deterioration on the PPBC scale from baseline</b>						
Herschorn, 2010 <sup>475</sup>	4 to 8	1013	0.46 (0.29; 0.74)	-0.055 (-0.091; -0.019)	-18 (-54; -11)	-55 (-91; -19)
<b>Deterioration on the UPS scale from baseline</b>						
Herschorn, 2010 <sup>475</sup>	4 to 8	1013	0.65 (0.36; 1.16)	-0.020 (-0.049; 0.009)		)
<b>≥2-point improvement on the PPBC scale</b>						
Dmochowski, 2010 <sup>474</sup>	4 to 8	883	1.29 (1.06; 1.57)	0.080 (0.019; 0.141)	13 (7; 54)	80 (19; 141)
<b>improvement on the UPS scale</b>						
Dmochowski, 2010 <sup>474</sup>	4 to 8	883	1.35 (1.13; 1.61)	0.108 (0.045; 0.171)	9 (6; 22)	108 (45; 171)
<b>≥2-point improvement on the PPBC scale from baseline</b>						
Herschorn, 2010 <sup>475</sup>	4 to 8	1013	0.94 (0.80; 1.11)	-0.024 (-0.088; 0.040)		
<b>improvement on the UPS scale from baseline</b>						
Herschorn, 2010 <sup>475</sup>	4 to 8	1013	1.28 (1.07; 1.52)	0.093 (0.030; 0.156)	11 (6; 33)	93 (30; 156)
<b>UTI</b>						
Herschorn, 2010 <sup>475</sup>	4 to 8	1013	3.69 (0.85; 16.04)	0.016 (0.002; 0.030)	62 (33; 436)	16 (2; 30)
Cardozo, 2010 <sup>476*</sup>	4	867	0.89 (0.43; 1.81)	-0.004 (-0.028; 0.020)		
	8	882	1.41 (0.74; 2.66)	0.014 (-0.012; 0.041)		

\*pooled analysis